Zentalis Pharmaceuticals, Inc. (ZNTL): Valuation
TTM figures as of June 30, 2026
Zentalis Pharmaceuticals, Inc. trades at a -38.56% free-cash-flow yield. That FCF yield is higher than 33% of its own month-end history back to 2020.
Earnings yield -41.99%.
77 month-end valuation observations are on file, starting April 2020.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is ZNTL cheap versus its own history?
Zentalis Pharmaceuticals, Inc. trades at a -38.56% free-cash-flow yield. That FCF yield is higher than 33% of its own month-end history back to 2020.
What is ZNTL's free-cash-flow yield?
Zentalis Pharmaceuticals, Inc. currently yields -38.56% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.